Beneficial Ownership Report · SCHEDULE 13G/A
Biohaven Ltd.
BHVNNYSEEQUITYCurrent
Beneficial Ownership Report
Structured filing — SCHEDULE 13G/A
primary_doc.xml
Amendment · This filing reports the amendment as submitted.
Subject company
- Company
- BIOHAVEN LTD.
- Company CIK
- 0001935979
- Street
- 215 CHURCH STREET
- City
- NEW HAVEN
- State / country code
- CT
- Postal code
- 06510
Statement details
- Amendment number
- 4
- Security class
- Common Shares
- Event date
- 09/30/2026
- Rule designation
- Rule 13d-1(b)
Reporting person 1
- Name
- JANUS HENDERSON GROUP Ltd.
- Citizenship / organization
- Y9
- Reporting person type
- HC
- Aggregate amount owned
- 2,036,197
- Percent of class
- 1.4
- Sole voting power
- 0
- Shared voting power
- 2,036,197
- Sole dispositive power
- 0
- Shared dispositive power
- 2,036,197
Item 1
Issuer
BIOHAVEN LTD.
Principal executive office address
215 CHURCH STREET NEW HAVEN, CT 06510
Item 2
Citizenship
Y9
Filing person
Janus Henderson Group Ltd. In accordance with SEC Release No. 34-39538 (January 12, 1998), this Schedule 13G reflects the securities beneficially owned, or deemed to be beneficially owned, by Janus Henderson Group Ltd. It does not include securities, if any, beneficially owned by Janus Henderson Group Ltd.s ultimate parent Janus Henderson Group Holdings, LLC, the direct or indirect owners of Janus Henderson Group Holdings, LLC, or other persons that may be deemed under control of such owners. Any beneficial ownership by such persons has been disaggregated from that of Janus Henderson Group Ltd. in accordance with the release.
Principal business or residence address
201 Bishopsgate EC2M 3AE, United Kingdom
Item 3
Not applicable indication
N
Type of filing person
HC
Item 4
Percent of class
1.4
Amount beneficially owned
Janus Henderson Group Ltd. (JHG) is the ultimate parent of a number of SEC-registered investment advisers and foreign equivalents thereof, including but not limited to Janus Henderson Investors US LLC, Janus Henderson Investors UK Limited, Janus Henderson Investors Australia Institutional Funds Management Limited, Janus Henderson Investors Middle East Limited, Janus Henderson Investors (Jersey) Limited, Janus Henderson Investors (Japan) Limited, Janus Henderson Investors (Singapore) Limited, Kapstream Capital Pty Limited, Privacore Capital Advisors LLC, Tabula Investment Management Limited, Victory Park Capital Advisors LLC, and Richard Berstein Advisors LLC (each, an Asset Manager and together, the Asset Managers). The Asset Managers generally exercise investment and/or voting discretion on behalf of their clients which include investment companies, other investment advisers, institutional separate accounts and retail separate accounts (collectively referred to herein as Managed Portfolios). As a result of their exercise of investment and/or voting discretion on behalf of the Managed Portfolios, the Asset Managers may be deemed to be the beneficial owner of 2,036,197 common shares of Biohaven Ltd. However, the Asset Managers do not have the right to receive any dividends from, or the proceeds from the sale of, the securities held in the Managed Portfolios and disclaim any ownership associated with such rights.
Sole voting power
0
Shared voting power
2036197
Sole dispositive power
0
Shared dispositive power
2036197
Item 5
Not applicable indication
Y
Ownership of 5% or less
N
Item 6
Not applicable indication
N
Ownership on behalf of another person
The Managed Portfolios have the right to receive all dividends from, and the proceeds from the sale of, the securities held in their respective accounts. Of the Managed Portfolios, none own more than five percent of the common shares of Biohaven Ltd.
Item 7
Not applicable indication
N
Subsidiaries
Please refer to Exhibit 99.
Item 8
Not applicable indication
N
Group members
N/A
Item 9
Not applicable indication
N
Item 10
Not applicable indication
N
Certifications
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
Exhibits
Exhibit 24: Power of Attorney Exhibit 99: Item 7
Signature 1
- Reporting person
- JANUS HENDERSON GROUP Ltd.
- Signed
- Kristin Mariani
- Title
- Head of North America Compliance
- Date
- 11/16/2026
Filed exhibits
- EXHIBIT 24: POWER OF ATTORNEY ↗PowerOfAttorney.txt
- EXHIBIT 99: ITEM 7 ↗Item_7.txt
Company context
Biohaven is a biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, obesity, neuroscience, and oncology. The Company is advancing its innovative portfolio of therapeutics, leveraging its proven drug development experience and multiple proprietary drug development platforms. Biohaven's extensive clinical and preclinical programs include Kv7 ion channel modulation for epilepsy; MoDE and TRAP extracellular protein degradation for immunological diseases; and myostatin inhibition for neuromuscular and metabolic diseases, including obesity.